LOS ANGELES, June 29, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other disorders, will present interim six-month safety and efficacy results from its Phase I/II HOPE-Duchenne clinical trial of CAP-1002 (allogeneic cardiosphere-derived cells) on a poster to be featured at the 2017 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference. The conference, which starts today and will run through July 2, is being held at the Chicago Marriott Downtown hotel in Chicago, Illinois. The poster will be made available on Capricor's website at http://capricor.com/news/events.

 (PRNewsfoto/Capricor Therapeutics, Inc.)

In an oral session to be held at the conference at 10:15 a.m. Central Time on Friday, June 30, Linda Marbán, Ph.D., Capricor's president and chief executive officer, will discuss the company's development plans in the Duchenne muscular dystrophy indication following its recent meeting with the U.S. Food and Drug Administration. This presentation may be accessed live at http://www.parentprojectmd.org/livestream.

Capricor expects to launch its next clinical trial of CAP-1002 for the treatment of Duchenne muscular dystrophy in the second half of 2017, subject to regulatory approval.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company developing first-in-class biological therapies. Capricor's lead candidate, CAP-1002, is a cell-based candidate currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. For more information, visit www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on March 16, 2017, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with prospectus supplements thereto, and in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on May 15, 2017. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. Capricor's exosomes technology, including CAP-2003, has not yet been approved for clinical investigation.

For more information, please contact:

AJ Bergmann, Vice President of Finance

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/six-month-results-from-capricors-hope-duchenne-trial-to-be-presented-at-the-2017-ppmd-annual-connect-conference-300481586.html

SOURCE Capricor Therapeutics, Inc.